Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy

Annals of Oncology

Volumn 8, Issue 5, 1997, Pages 477-483

  Bower, M ^a   Newlands, E S ^a   Holden, L ^a   Rustin, G J S ^b   Begent, R H J ^c  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Germ cell tumour; Non seminomatous; Teratoma

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; TUMOR MARKER; VINCRISTINE;

ACUTE MYELOMONOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; COMBINATION CHEMOTHERAPY; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030839120     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008279222625     Document Type: Article

References (41)

1. Peckham MJ, Barrett A, Liew KH et al. The treatment of metastatic germ-cell testicular tumours with bleomydn, etopo-side and cisplatin (BEP). Br J Cancer 1983; 47: 613-9.
2. Mead G. International Consensus Prognostic Classification for metastatic germ cell tumours treated with cisplatin based chemotherapy: final report of the international germ cell cancer collaborative group (IGCCCG). Proc ASCO 1995; 14: 235.
3. Daugaard G, Rorth M. High dose cisplatin and VP-16 with bleomycin, in the management of advanced metastatic germ cell tumours. Eur J Cancer Clin Oncol 1986; 22: 477-85.
4. Ozols R, Ihde D, Linehan W et al. Randomised trial of standard chemotherapy vs. high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ cell tumours. J Clin Oncol 1988; 6: 1031-40.
5. Nichols C, Williams S, Loehrer P et al. Randomised study of cisplatin dose intensity in poor-risk germ cell tumors: A southeastern cancer study group and southwest oncology group protocol. J Clin Oncol 1991; 9: 1163-72.
6. Wettlaufer JN, Feiner AS, Robinson WA. Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors. Cancer 1984; 53: 203-9.
7. Harwich A, Brada M. Nicholls J et al. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol 1989; 25: 177-84.
8. Motzer RJ, Mazumdar M, Gulati SC et al. Phase II trial of highdose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-35.
9. Chevreau C. Droz JP, Pico JL et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 1993; 23: 213-7.
10. Logothetis CJ, Samuels ML, Selig D et al. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 1985; 3: 326-35.
11. Bosl GJ, Geller NL, Vogelzang NJ et al. Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J Clin Oncol 1987; 5: 436-40.
12. Lewis C, Fossa S, Mead G et al. BOP/VIP: A new cisplatinintensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 1991; 2: 203-11.
13. Newlands ES, Begent RH, Ruslin GJ et al. Further advances in the management of malignant teratomas of the teslis and other sites. Lancet 1983; 1: 948-51.
14. Mead GM, Stenning SP, Parkinson MC et al. The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumours. J Clin Oncol 1992; 10: 85-94.
15. Rustin GJ, Newlands ES, Bagshawe KD et al. Successful management of metastatic and primary germ cell tumors in the brain. Cancer 1986; 57: 2108-13.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
17. Pelo R, Pike M, Armilage P et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: II analysis and examples. Br J Cancer 1977; 35: 1-39.
18. Cox D, Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
19. Read G, Stenning S, Cullen M et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992; 10:715-20.
20. Bajorin D, Prognostic classification in metastatic non-seminoma. In Horwich A (ed): Testicular Cancer-Clinical Investigation and Management. London: Chapman & Hall 1991; 125-45.
21. Hendry WF, A'Hern RP. Hetherington JW et al. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: Prognostic value and therapeutic benefit. Br J Urol 1993; 71: 208-13.
22. Gerl A, Clemm C, Schmeller N et al. Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 1995; 6: 483-8.
23. Hitchins RN, Newlands ES, Smith DB et al. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: Comparison of commonly used classification systems of good and poor prognosis. Br J Cancer 1989; 59: 236-42.
24. Broun E, Nichols C, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124-8.
25. Nichols C, Andersen J, Lazarus H et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An eastern cooperative oncology group protocol. J Clin Oncol 1992; 10: 558-63.
26. Motzer RJ, Gulati SC, Crown JP et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer 1992; 69 (2): 550-6.
27. Cullen MH, Harper PG, Woodroffe CM et al. Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime. Br J Urol 1988; 62: 454-60.
28. Husband DJ, Green JA. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: Outcome and importance of dose intensity. Eur J Cancer 1992; 28: 86-91.
29. Stoter G, Kaye S, Sleyfer D et al. Preliminary results of BEP (bleomycin, etoposide. cisplatin) versus an alternating regimen of BEP and PVB (cisplatin, vinblastine, bleomycin) in high volume metastatic testicular non-seminoma. An EORTC study. Proc ASCO 1986; 5: 106.
30. Horwich A, Wilson C, Corns P et al. Increasing the dose intensity of chemotherapy in poor-prognosis metastatic nonseminoma. Eur Urol 1993; 23: 219-22.
31. Doll DC, List AF, Greco FA et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105: 48-51.
32. Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19: 253-6.
33. Lederman GS, Garnick MB. Pulmonary emboli as a complication of germ cell cancer treatment. J Urol 1987; 137: 1236-7.
34. Boyer M, Raghavan D, Harris P et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990; 8: 21-6.
35. Gietema JA, Sleijfer DT, Willemse PH et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992; 116:709-15.
36. Bokemeyer C, Berger C, Kuczyk M et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14: 2923-32.
37. Boshoff C, Begent RH, Oliver RT et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 1995; 6: 35-40.
38. Pedersen-Bjergaard J, Philip P. Two different classes of therapy-related and de now acute myeloid leukemia? Cancer Genet Cytogenet 1991; 55: 119-24.
39. Nichols CR, Roth BJ, Heerema N et al. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 1990; 322: 1425-9.
40. Bokemeyer C, Schmoll H-J. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993; 11: 1703-9.
41. van Leeuwen FE, Stiggelbout AM, van den Belt Dusebout AW et al. Second cancer risk following testicular cancer: A follow-up study of 1,909 patients. J Clin Oncol 1993; 11: 415-24.